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Abstract 27 
There is an ever increasing amount of evidence to support the hypothesis that 28 
complement (C)1q, the first component of the classical complement pathway, is involved in 29 
the regulation of cancer growth, in addition to its role in fighting infections. It has been 30 
demonstrated that C1q is expressed in the microenvironment of various types of human 31 
tumor, including breast adenocarcinomas. This study compares carcinogenesis progression in 32 
C1q deficient (neuT-C1KO) and C1q competent neuT mice in order to investigate the role of 33 
C1q in mammary carcinogenesis. Significantly accelerated autochthonous neu+ carcinoma 34 
progression was paralleled by accelerated spontaneous lung metastases occurrence in C1q 35 
deficient mice. Surprisingly, this effect was not caused by differences in the tumor infiltrating 36 
cells or in the activation of the complement classical pathway, since neuT-C1KO mice did not 37 
display a reduction in C3 fragment deposition at the tumor site. By contrast, a significant 38 
higher number of intratumor blood vessels and a decrease in the activation of the tumor 39 
suppressor WW domain containing oxidoreductase (WWOX) were observed in tumors from 40 
neuT-C1KO as compared to neuT mice. In parallel, an increase in Her2/neu expression was 41 
observed on the membrane of tumor cells. Taken together, our findings suggest that C1q plays 42 
a direct role both on halting tumor angiogenesis and on inducing apoptosis in mammary 43 
cancer cells by coordinating the signal transduction pathways linked to WWOX and, 44 
furthermore, highlight the role of C1q in mammary tumor immune surveillance regardless of 45 
complement system activation.  46 
 4
Introduction 47 
It has now been clearly demonstrated that the survival and progression of a primary 48 
tumor depend on three major events: immune evasion, angiogenesis and metastasis. These 49 
complex biological processes can be promoted and halted by a number of factors, including 50 
complement cascade components. 1 There is sufficient evidence to demonstrate the presence 51 
of complement deposition on tumor tissues from patients in a variety of cancer types. 2,3 52 
Nevertheless, the role of the complement system in tumor growth and metastatic spread has 53 
not yet been sufficiently addressed, and contradictory findings are still being reported. 4,5 54 
C1, the first component of the classical complement pathway, is a multimolecular 55 
complex composed of C1q, C1r and C1s molecules that associate in a calcium-dependent 56 
macromolecular complex. C1q, the ligand recognition subcomponent of the complex, is 57 
composed by six heterotrimeric structures, made of A (C1qA), B (C1qB) and C (C1qC) chains, 58 
with a collagen-like and a C-terminal globular region; the latter is the moiety responsible for 59 
ligand binding. 6 When C1q binds to IgM or clustered IgG on immunocomplexes, or to surface-60 
bound pentraxins, other complement cascade components are sequentially activated leading 61 
to the generation of effector molecules which are able to limit infection by pathogens and play 62 
an essential homeostatic role in the clearance of damaged self-antigens, immune complexes, 63 
altered self, and apoptotic cells. 7 64 
Besides this role in the activation of the classical complement pathway through the 65 
recognition of immune complexes, 8 it is now recognized that C1q can carry out functions that 66 
are unrelated to complement activation. Recent studies have demonstrated its involvement in 67 
several physiological processes via binding with its specific receptors. 9 Among the processes 68 
induced by the non-classical functions of the C1q molecule, we find: the modulation of various 69 
immune cells, 10 the regulation of cell migration (chemotaxis), adhesion, survival and 70 
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differentiation, 11 coagulation, 12 angiogenesis 13 and embryonic development, including 71 
neurological synapse function. 14 72 
There is mounting evidence to support the idea that C1q and its receptors are also 73 
involved in the regulation of cancer. The recently postulated ability of C1q to induce apoptosis 74 
in prostate cancer cells by coordinating signal transduction pathways linked to the tumor 75 
suppressor WW domain containing oxidoreductase (WWOX), 15 has highlighted its important 76 
role as a humoral factor which is needed to directly block cancer cell proliferation, without 77 
the involvement of anti-tumor antibodies and the consequent activation of the classical 78 
complement pathway. The direct anti-tumor effect played by C1q is also highlighted by the 79 
fact that it is significantly down-regulated in benign prostatic hyperplasia and prostate cancer 80 
despite being expressed in normal prostate tissues. 15 Furthermore, recent data demonstrate 81 
that C1q receptors (C1qR) expression is up-regulated on almost all types of malignant cells. 9 82 
Interestingly, two of the best-known C1qR, 16 cC1qR and gC1qR, have opposite functions; 83 
while cC1qR is detrimental to tumor growth because it is a pro-phagocytic signal, gC1qR 84 
promotes tumor cell growth, angiogenesis and metastases formation. 9 Moreover, tumor cells 85 
not only express gC1qR on their membrane but they can also secret it into the tumor 86 
microenvironment, protecting cancer cells from C1q-induced apoptosis by impounding the C1 87 
molecule. Soluble gC1qR, has also a role to play, by activating the complement system, in the 88 
generation of potent vasoactive peptides which are able to enhance vascular permeability, 89 
thus facilitating tumor cell escape and consequent metastatization. 9 90 
A growing number of papers in recent years have linked the expression of the 91 
complement cascade components and regulators to the prognosis of breast cancer patients. 92 
17,18 CD59, a membrane complement regulatory protein, has recently been found to be 93 
overexpressed in breast cancer where it facilitates tumor cell escape from complement 94 
surveillance. 19 Significantly differential complement cascade pathway expression was 95 
 6
observed in luminal A, luminal B, basal-like and Her2+ mammary cancers. 20 The complement 96 
factor C1q, which was found to be down-regulated, appears to play a noteworthy and 97 
important role in this context. 18 However, the mechanisms that underlie the effects exerted 98 
by C1q on breast cancer progression have not yet been sufficiently clarified, meaning that 99 
deeper understanding of the molecular interactions between tumors and C1q may lead to the 100 
identification of additional pathways and targets which can be exploited for combined 101 
therapy. 102 
The genetic predisposition of rat Her2/neu transgenic (neuT) mice to developing lethal 103 
mammary carcinomas, characterized by well-defined gene expression signature, 21 104 
progression and long lasting interaction with the host microenvironment, make these mice an 105 
appealing model for the evaluation of the role of immunosurveillance. 22,23 We have 106 
previously demonstrated that there is a deposition of C3 on tumor cells and vessels during 107 
Her2/neu-driven mammary carcinogenesis in neuT mice and that natural antibodies which 108 
are directed against antigens expressed by tumor cells arise concomitantly. 24 These 109 
observations suggest that complement activation through the classical pathway may play a 110 
key role in tumor immunosurveillance. To verify this hypothesis, the present work sees us 111 
generate neuT mice that are deficient for the C1qA molecule (neuT-C1KO mice) and then 112 
evaluate the progression of carcinogenesis in their mammary glands in comparison to neuT 113 
mice. Surprisingly, our data demonstrate that C1q can act as tumor-inhibiting factor, 114 
regardless of complement activation. 115 
 116 
Results 117 
Autochthonous Her2/neu+ carcinoma progression is accelerated in C1q deficient 118 
mice.  119 
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Significantly accelerated tumor incidence was observed when mammary carcinogenesis 120 
was evaluated in neuT-C1KO mice, with 100% of mice already bearing a palpable tumor at 121 
week 19 of age, when 50% of neuT mice were still free from palpable tumors (Fig. 1A; 122 
p<0.0001, Log-rank Mantel-Cox test). The lack of the C1q molecule in neuT mice also impacts 123 
on tumor multiplicity and tumor growth. Indeed, from the 17th week of age (Fig. 1B; p values 124 
ranging from p=0.04 to p<0.0001, Student’s t-test), a significant increase in tumor multiplicity 125 
was observed in neuT-C1KO mice, as compared to neuT mice, and tumors grew significantly 126 
more quickly (Fig. 1C; p=0.001, Student’s t-test). A histological analysis of mammary glands 127 
from 11-, 15- and 17-week-old mice confirmed that progression from hyperplastic lesions to 128 
in situ and diffuse carcinomas was accelerated in neuT-C1KO mice (Fig. 1D-I). By week 11, the 129 
hyperplastic lesions appeared to be more numerous than those in neuT mice (Fig. 1D, G). At 130 
week 15, neuT-C1KO mice displayed multifocal lesions, which were larger and evenly more 131 
spread throughout the mammary gland than those observed in neuT mice (Fig. 1E, H). By 132 
week 17, these lesions converged into multiple, large nodules similar to in situ carcinomas 133 
that were more diffused and expanded than in neuT mice (Fig. 1F, I). Nevertheless, 134 
carcinomas progressing in neuT-C1KO and neuT mice displayed a similar grade of 135 
differentiation (Fig. 1J, K). However, a significantly higher number of PCNA+ tumor cells was 136 
found in carcinomas from neuT-C1KO as compared to neuT mice suggesting an increasing 137 
tumor cell proliferation in complement C1q deficient neuT mice (Fig. 1L; p=0.001, Student’s t-138 
test). In addition, even if very few apoptotic cells were detectable in the mammary tumors 139 
from both neuT and neuT-C1KO mice, a significant decrease in the number of Caspase-3+ cells 140 
was observed in mice lacking C1q (Fig. 1M-O; p=0.002, Student’s t-test), suggesting a 141 
decreased apoptosis in the absence of C1q molecule. 142 
The accelerated tumor onset observed in neuT-C1KO mice was paralleled by a 143 
significantly accelerated spontaneous lung metastasis development. Indeed, at week 17, when 144 
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neuT mice were completely free from lung metastases, 36% of neuT-C1KO mice displayed 145 
Her2/neu+ nodules in their lungs (Fig. 2A-C, p=0.05, Chi-square test). This accelerated 146 
metastatization suggests that the epithelial-to-mesenchymal transition (EMT) occurs earlier 147 
in neuT-C1KO tumors. In order to investigate this issue, we evaluated the neuT and neuT-148 
C1KO tumor expression of E-Cadherin, whose functional loss or down-regulation is 149 
considered a hallmark of EMT. 25 Moreover, since a link a between C3 overexpression, C3a 150 
generation and EMT has been recently reported, 26 we also evaluated the expression of E-151 
Cadherin in the tumors from neuT mice deficient for the C3 molecule (neuT-C3KO mice). 152 
Western blotting showed significantly lower E-cadherin expression in neuT-C1KO and neuT-153 
C3KO as compared to neuT tumors (Fig. 2D-E; p<0.05, Student’s t-test). We used fluorescence 154 
microscopy (Fig. 2F-I) to confirm the immunoblot findings and determine the localization of 155 
E-cadherin in tumor cells. While tumor cells from neuT mice displayed E-cadherin expression 156 
at contact sites between cells (Fig. 2F), tumor cells from neuT-C1KO (Fig. 2G) and neuT-C3KO 157 
(Fig. 2H) mice provided almost negative staining and fluorescent signal quantification 158 
showed significantly lower E-cadherin expression in neuT-C1KO and neuT-C3KO than in neuT 159 
mice (Fig. 2I; p<0.0001, p= 0.04, Student’s t-test, respectively). 160 
 161 
Accelerated carcinogenesis in neuT-C1KO mice is independent of the absence of 162 
the classical complement activation pathway.  163 
The accelerated pace of tumor progression in neuT-C1KO mice points towards a key role 164 
for the complement system in hampering Her2/neu autochthonous mammary tumor 165 
progression, as previously demonstrated in neuT-C3KO mice. 24 The contribution of C1q to 166 
tumor immunosurveillance should mainly be due to the triggering of the classical pathway of 167 
complement activation that occurs after binding with natural anti-tumor antibodies present 168 
in the sera of tumor-bearing mice. 24 If this were the case, C3 fragments deposition in the 169 
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mammary glands would be drastically lower in neuT-C1KO mice than in neuT. Nevertheless, 170 
the confocal immunofluorescence microscopy analysis of tumors after staining with anti-171 
C3b/iC3b/C3c antibodies showed that comparable levels of C3 cleavage products are present 172 
in neuT and neuT-C1KO tumors (Fig. 3A, B, D). Moreover, as previously observed in neuT 173 
mice, 24 C3 cleavage products were clearly evident both in the tumor vasculature and stroma 174 
of mammary tumors developing in neuT-C1KO mice (Supplementary Fig. S1). A further 175 
investigation was therefore performed on neuT mice that were deficient in antibody 176 
production (neuT-BKO mice). 27 C3 deposition in neuT-BKO tumors was similar to that 177 
observed in neuT and neuT-C1KO mice (Fig. 3C, D), confirming that complement activation is 178 
independent of the classical pathway in neuT mice.  179 
 180 
C1q deficiency is associated with decreased activation of the oncosuppressor 181 
WWOX and increased Her2/neu expression 182 
The influence of C1q on tumor progression does not appear to be due to complement 183 
cascade activation and so we decided to determine whether it acts on the tumor cell 184 
phenotype directly. Recent studies have reported that C1q protein may induce the apoptosis 185 
of cancer cells during the initial hyperplasia and cancerous stages of cancer progression by 186 
activating the tumor suppressor WWOX pathway. 15 In order to study whether a correlation 187 
between C1q deficiency and WWOX activation exists in neuT tumors, immunofluorescence 188 
staining of tumors from neuT and neuT-C1KO mice was performed. While clear positivity for 189 
the phospho (p) WWOX protein was observed in neuT tumor cells (Fig. 4A, D), it was found to 190 
be significantly reduced in neuT-C1KO mice (Fig. 4B, D; p=0.01, Student’s t-test). 191 
Interestingly, a similar reduction in pWWOX was also observed in tumors from neuT-C3KO 192 
mice (Fig. 4C, D; p=0.02, Student’s t-test), despite the C1qA gene not being knocked out in 193 
these mice. However, significantly lower levels of C1q fragment deposition were observed at 194 
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the tumor site in neuT-C3KO than in neuT mice (Fig. 4E-H; p=0.009, Student’s t-test). The 195 
confocal immunofluorescence microscopy analysis of tumors after staining with anti-C1q and 196 
CD31 antibodies showed that C1q was deposited mainly in the tumor vasculature in both 197 
neuT and neuT-C3KO mice (Supplementary Fig. S2). 198 
Since neuT tumors are strictly addicted to Her2/neu, 28 we evaluated its expression 199 
using confocal immunofluorescence microscopy. As compared to tumors in neuT mice (Fig. 200 
4I, L), Her2/neu protein expression was significantly increased in neuT-C1KO tumors (Fig. 4J, 201 
L; p=0.05, Student’s t-test). This enhanced expression was similar to what observed in neuT-202 
C3KO (Fig. 4K, L; p=0.02, Student’s t-test) tumors. Her2/neu appeared to be expressed mainly 203 
at the cell membrane of neuT tumor cells and its expression appeared to be higher and 204 
broader in both complement-deficient strains. 205 
 206 
C1q deficiency affects tumor vessel density but not the frequency of tumor-207 
infiltrating leukocytes. 208 
Our data indicate that the more aggressive phenotype of neuT-C1KO, as compared to 209 
neuT tumors (Fig. 1), may be a result of the reduced activation of tumor suppressor WWOX 210 
and the consequent survival of tumor cell clones that present stronger Her2/neu oncoprotein 211 
expression. To evaluate whether C1q deficiency also impacts on the tumor microenvironment, 212 
we evaluated the vessel density (Fig. 5A-H) and the frequency of tumor-infiltrating immune 213 
cells (Fig. 5I-M) in neuT, neuT-C1KO and neuT-C3KO tumors of equivalent size. 214 
Immunohistochemical staining for endothelial cell markers (Fig. 5A-C) displays a 215 
statistically higher number of intratumor vessels in neuT-C1KO as compared to neuT and 216 
neuT-C3KO mice (Fig. 5D; p=0.04, Student’s t-test). On the other hand, the assessment of 217 
vessel diameter indicates that, although higher in number, tumor-associated blood vessels in 218 
neuT-C1KO tumors are similar in dimension when compared to those of neuT mice (Fig. 5E-F, 219 
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H). By contrast, as previously reported 24, significantly larger intratumor vessels are evident 220 
in carcinomas developing in the absence of C3 (Fig. 5G-H; p<0.0001 Student’s t-test). 221 
The frequency of tumor-infiltrating immune cells was evaluated using flow-cytometry. 222 
Tumors of neuT and neuT-C1KO mice displayed no statistically significant differences in the 223 
frequency of T regulatory (Treg) cells, CD4+, CD8+ and γδ T cells, natural killer (NK) cells, 224 
macrophages and myeloid-derived suppressor cells (MDSC) (Fig. 5I-M). These data suggest 225 
that the C1q molecule is not involved in regulating leukocyte recruitment at the tumor site. 226 
This is in contrast to observations in C3 deficient mice which instead show a significant 227 
increase in infiltrating Treg cells (Fig. 5I; p=0.005, Student’s t-test), as previously shown, 24 228 
and a significant reduction in NK cells (Fig. 5L; p=0.005, Student’s t-test). These differences, 229 
together with those in vessel dimension and complement activation, justify the fact that neuT-230 
C1KO tumors are less aggressive than those of neuT-C3KO mice (Fig. 6A, B; p=0.05 and 231 
p=0.02, Log-rank Mantel-Cox test) despite showing comparable levels of pWWOX and 232 
Her2/neu expression (Fig.  4D, L).  233 
 234 
Discussion 235 
Several studies have suggested that the complement system plays a critical role in 236 
cancer growth and spread. It has been demonstrated that cancer cells establish a balance 237 
between complement activation and inhibition. 29 However, controversial and conflicting data 238 
on the complement system’s tumor-promoting, 30,31 and inhibiting activities, 24 have been 239 
published, 2 and the mechanisms of complement-specific activities in the tumor 240 
microenvironment are still unclear and demands further study.  241 
The use of genetically engineered mice, which are predestined to develop fatal tumors 242 
and are knocked out for one of the key complement cascade molecules, enabled us to test the 243 
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role of complement activation in cancer growth and development and will possibly lead to the 244 
design of complement-related anticancer strategies. 245 
We have recently exploited the genetic predestination of neuT female mice to mammary 246 
carcinogenesis to assess the weight of C3 complement-mediated 24 immune surveillance in 247 
the development of autochthonous carcinomas. The data obtained demonstrated that the loss 248 
of C3 activation, whose fragments were found to specifically accumulate in vessels and stroma 249 
in and around the incipient cancers, was responsible for the dramatic increase in the 250 
aggressiveness of neu+ mammary tumors. Concomitantly, as had already been demonstrated 251 
in cancer patients, 32,33,34 spontaneous antitumor antibodies increased in neuT mice during 252 
the course of tumor progression. 24 Taken together, these observations suggest that the 253 
complement system can take on a tumor-inhibiting role that is played out through the 254 
activation of the classical pathway.  255 
The involvement of classical complement pathway activation in tumor cell killing was 256 
further investigated by generating neuT-C1KO mice. An accelerated carcinoma progression 257 
was evident in these mice. The comparable level of C3 fragment deposition observed in the 258 
mammary glands of neuT-C1KO mice and neuT-BKO mice, which are unable to produce 259 
antibodies, highlight the fact that tumor cell killing is not related to complement classical 260 
pathway activation in neuT mice. By contrast, the decreased activation of the oncosuppressor 261 
WWOX and the over-expression of the neuT protein on the mammary tumor cells found in 262 
neuT-C1KO mice point to the key and direct role that C1q plays in tumor cell elimination. 263 
Indeed, recent data have highlighted the existence of non-canonical functions that are exerted 264 
by C1q on several types of cells, including cancer cells. Irrespectively of the beneficial or 265 
harmful impact that the complement system has on tumor growth, the C1q molecule’s 266 
contribution to tumor progression and metastasization has been demonstrated regardless of 267 
complement activation, both in prostatic cancer cells 15, 35 and very recently in  melanoma. 31  268 
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These results provide a new perspective on our previously published data which 269 
demonstrated that the neuT up-regulation on tumor cells observed in neuT-C3KO tumors was 270 
not only directly dependent on lack of C3 activation. In particular, the extremely aggressive 271 
phenotype displayed by neuT-C3KO tumors can also be caused by the impaired activation of 272 
WWOX, which is a result of the unexpected lack of C1q deposition on the tumor site of neuT-273 
C3KO mice. A relationship between C1q-induced expression and hypoxia has been 274 
demonstrated in neurons. 36 Although the mechanisms by which C1q mRNA expression is up-275 
regulated by hypoxia remain to be investigated, it has been demonstrated that cultured cells, 276 
which did not express C1q before hypoxia, did express C1q mRNA and protein during and 277 
after hypoxia, respectively. 36 It has recently been demonstrated, by both 278 
immunohistochemistry and western blotting experiments, that neuT tumor cells express a 279 
low but detectable level of HIF1 protein. 37 Similar amounts of HIF1 protein were also 280 
observed in neuT-C1KO tumors, while it was almost absent in neuT-C3KO tumors 281 
(Supplementary Fig. S3 A-C). These data, together with the previously reported increased 282 
blood vessel permeability and reduced necrotic areas within neuT-C3KO neoplasms, as 283 
compared with neuT lesions, suggest that the hypoxic phenotype of neuT-C3KO is lower than 284 
that of both neuT and neuT-C1KO tumors. 24 Altogether, these observations lead to speculate 285 
that the unexpected lack of the C1q protein observed in neuT-C3KO tumors may be due to the 286 
fact that C1q mRNA transcription is not up-regulated by hypoxia in these tumors, as it is in 287 
neuT and neuT-C1KO tumors. Indeed, using the LASAGNA-Search tool 38 288 
(http://biogrid.engr.uconn.edu/lasagna_search/) to perform binding sites searches on mouse 289 
C1q promoter, we confirmed the presence of  binding sites specific for the transcriptional 290 
factors RelA, 39 Meis-1a, 40 AhR 41 and Arnt, 42 known to be present on human C1q promoter 291 
and linked to hypoxia (GeneCards®, Human Gene Data base; http://www.genecards.org/cgi-292 
bin/carddisp.pl?gene=C1QA&keywords=c1qa). 293 
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Contradictory effects of complement in modulating vascularization and angiogenesis are 294 
described in the literature. 30,31,43 Our immunohistochemistry data showed a marked 295 
deposition of C1q on vascular endothelium and stroma of neuT tumors. On the other hand, the 296 
increased tumor vascularization observed in neuT-C1KO mice suggests that C1q could be 297 
considered an inhibitor of tumor angiogenesis, at least in our model of autochthonous Her2-298 
driven mammary cancer that display a process of angiogenesis 44 not superimposable to that 299 
observed in transplantable tumors. 31  Further investigations are warranted to define the 300 
underlying mechanisms of this C1q-mediated inhibition of tumor vasculature. 301 
The hypothesis that C1q may have an effect in the induction of an immunosuppressive 302 
tumor microenvironment, was excluded by an analysis of tumor infiltrating lymphocytes. 303 
Contrary to results in tumors from neuT-C3KO mice, 24 no differences in the percentages of 304 
myeloid derived suppressor cells and Treg cells were found. The significant reduction in NK 305 
cells in tumors from neuT-C3KO mice, as compared to both neuT and neuT-C1KO tumors, is 306 
certainly worthy of note. The lack of a C1q-induced immunosuppressive tumor phenotype, 307 
together with the presence of a significant amount of NK cells, can help explain why neuT-308 
C1KO tumors are less aggressive than their neuT-C3KO analogues. Indeed, NK cells can lyse 309 
tumor cells after the recruitment of complement receptor 3 (CR3) by iC3b, especially when 310 
MHC class I molecules are poorly expressed. 45 NeuT+ tumor cells are susceptible to the 311 
activity of NK cells, as an inverse correlation exists between the expression levels of neuT 312 
protein and those of MHC class I molecules as well as other components of the antigen-313 
processing machinery. 46 Moreover, signaling through the Her2/Her3 pathway in breast 314 
tumor cell lines has been shown to enhance their recognition by NK and T cells thanks to the 315 
killer cell lectin-like receptor subfamily K, member 1 (KLRK1, or NKG2D). 47 316 
In conclusion, our data demonstrate that the C1q protein protects against the 317 
development of Her2/neu+ mammary carcinomas, at least in our preclinical BALB-neuT 318 
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female mouse model. The tumor-inhibiting C1q-mediated effects do not appear to be 319 
associated with the classical pathway of complement, but with its direct role on endothelial 320 
and tumor cells. Based on our results and on data from the literature we propose the 321 
following mechanism of C1q direct antitumoral role in neuT mammary carcinogenesis. The 322 
C1q binding with its receptor leads to the phosphorylation and consequent activation of 323 
WWOX, which is a known oncosuppressor required to block cancer cell proliferation. 15 324 
Indeed, activated WWOX may induce the apoptosis of mammary tumor cancer cells, probably 325 
by interacting with p53, 48 and inhibit the EMT processes through the expression of E-326 
Cadherin. Conversely, the lack of C1q prevents WWOX activation leading to tumor cell growth 327 
and metastases formation. As far as the mechanisms linking the absence of C1q and the 328 
increased levels of neuT protein expression on mammary tumor cells are concerned, our 329 
hypothesis is that WWOX activation may be involved in neuT post-translational negative 330 
regulation (Fig. 7). By contrast, WWOX-dependent transcriptional regulation of neuT gene is 331 
unlikely since this transgene is under the control of the MMTV promoter and not of the 332 
endogenous one.  333 
However, as expected for a system with various distinct activities, this protective role in 334 
mammary cancer does not appear to be applicable to every tumor type. Indeed, recent 335 
findings have highlighted C1q’s role as a cancer-promoting factor in a transplantable model of 336 
melanoma. 31 However, numerous variables, including the genetic background of mice used, 337 
the type of tumors and especially the use of transplantable instead of autochthonous tumors, 338 
may all influence how the complement system affects tumor progression, culminating in very 339 
different biological outcomes. Moreover, considering the opposite function exerted by the two 340 
known C1qR, we can speculate that the tumor inhibiting- or promoting- effect mediated by 341 
the C1q protein may results from different degrees of cC1qR or gC1qR expression in the 342 
tumor. 343 
 16
Nevertheless, it is important to note that C1q can exert its functions directly on tumor 344 
cells, independently of complement activation pathways, both in breast cancer and in 345 
melanoma. Defining the role of C1q in different tumor types may lead to new drugs in the 346 
clinic, thanks to its role as a major contributor to the immunosurveillance and control of 347 
cancer progression as well as tumor growth and dissemination. 348 
 349 
Materials and methods 350 
Mice. BALB/c mice that were deficient for the C1qA (BALB-C1KO) and C3 (BALB-C3KO) 351 
complement component were provided by Prof. Marina Botto (Imperial College, London, UK). 352 
49 NeuT male mice 28 from Biogem (Ariano Irpino, Italy) were crossed with BALB-C1KO and 353 
with BALB-C3KO females in order to obtain neuT+ C1+/- and neuT+ C3+/- heterozygous male 354 
mice, respectively. These heterozygous male mice were then crossed with BALB-C1KO and 355 
BALB-C3KO females; the progeny was genotyped in order to identify neuT+ C1-/- (neuT-C1KO) 356 
and neuT+ C3-/- (neuT-C3KO) female mice that were then used in the experiments. NeuT-BKO 357 
mice were generated by crossing neuT mice with BALB/c mice KO for the immunoglobulin μ 358 
chain gene, as previously described. 27 The mammary glands of all neuT mice were inspected 359 
and palpated twice a week for tumor appearance. Individual neoplastic masses were 360 
measured with calipers in two perpendicular diameters and the average value was recorded. 361 
Progressively growing masses > 1 mm in mean diameter were regarded as tumors. Neoplastic 362 
growth was monitored until the first tumor that exceeded a mean diameter of 10 mm was 363 
found, at which point mice were euthanized for ethical reasons. Tumor multiplicity was 364 
calculated as the cumulative number of incident individual tumors/total number of mice and 365 
is reported as mean ± SEM. All mice were maintained at the Molecular Biotechnology Center, 366 
University of Torino, in specific pathogen free conditions (Allentown Caging Equipment, 367 
Allentown Inc., Allentown, NJ) and treated in conformity with current European guidelines 368 
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and policies. The Bioethical Committee of the University of Torino approved the experimental 369 
plan. 370 
 371 
Morphological analyses. The whole mount preparation of mammary glands was 372 
carried out by removing the mouse skin and fixing it overnight in 10% buffered formalin. 373 
Mammary fat pads were scored into quarters and gently scraped from the skin. These were 374 
immersed in acetone overnight and then rehydrated and stained in ferric hematoxylin 375 
(Sigma-Aldrich), dehydrated in increasing concentrations of alcohol, cleared with histo-376 
lemon, and stored in methyl salicylate (Sigma-Aldrich). Digital pictures were taken using a 377 
Nikon Coolpix 995 (Nital, Medley, FL) mounted on a stereoscopic microscope (MZ6; Leica 378 
Microsystems, Milano, Italy) and analyzed as previously described in detail. 50 379 
 380 
Histology, immunohistochemistry and immunofluorescence. Lung samples from 14 381 
neuT and 19 neuT-C1KO 17 week-old mice were fixed in formalin and embedded in paraffin. 382 
To optimize the detection of microscopic metastases and ensure systematic uniform and 383 
random sampling, lungs were processed as previously described. 24 For the evaluation of 384 
spontaneous metastases of all the experimental groups, sections were stained with 385 
hematoxylin/eosin and with anti-Her2 immunohistochemistry. Metastases were counted 386 
independently by two pathologists in a blind fashion. 387 
Mammary glands were fixed in formalin and embedded in paraffin or fixed in 388 
paraformaldehyde 1% and frozen in a cryo-embedding medium (OCT, Bioptica) for 389 
histological and immunohistochemical analyses. Six to eight mm mammary tumors were fixed 390 
in paraformaldehyde 1% and frozen in a cryo-embedding medium (OCT, Bioptica).  391 
Sections were incubated with the mouse monoclonal anti-PCNA antibody (Dako 392 
Corporation, M0879), rabbit anti-active caspase-3 (R&D systems, AF835), rabbit anti-human 393 
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Her-2 (Dako Corporation, A0485), rabbit anti-mouse E-Cadherin (Cell Signaling, 24E10), 394 
rabbit anti-phospho-WWOX (pTyr33) (Sigma-Aldrich, SAB4504681), rat anti-mouse C1q 395 
(Abcam, ab11861), rat anti-mouse C3b/iC3b/C3c mAb (HyCult biotech, 2/11), rat anti-CD105 396 
(BD Pharmingen, 550546) and rat anti-CD31 (BD Pharmingen, 550274). For 397 
immunohistochemical staining, sections were then incubated with the appropriate 398 
biotinylated secondary antibody (Jackson Immunoresearch Laboratories). Immunocomplexes 399 
were detected using NeutrAvidin™ Alkaline Phosphatase Conjugated (Thermo Scientific-400 
Pierce Biotechnology) and Vulcan Fast Red (Biocare Medical) or Streptavidin Peroxidase 401 
(Thermo Scientific) and DAB Chromogen System (DakoCorporation). For 402 
immunofluorescence analysis, sections were then incubated with the appropriate Alexa 488 403 
and 546 labeled secondary antibodies (all from Molecular Probes); nuclei were stained with 404 
DAPI (Sigma-Aldrich) or TO-PRO®-3 iodide (Thermo-Fisher Scientific). Images were acquired 405 
on a Zeiss ApoTome fluorescence microscope (Axiovert 200M, Zeiss, Jena, Germany) and 406 
captured using a CCD cool digital camera (Zeiss) or on a Zeiss LSM 510 META confocal 407 
microscopy. 408 
The percentage of PCNA+ tumor cells was evaluated counting positive and negative 409 
cells on the digital images of 10 neuT and 10 neuT-C1KO tumors (3 ×400 microscopic fields 410 
per tumor) by 2 pathologists, independently and in a blind fashion. 411 
The number of activated Caspase 3+ tumor cells was evaluated counting positive cells 412 
on the digital images of 10 neuT and 10 neuT-C1KO tumors (3 ×200 microscopic fields per 413 
tumor) by 2 pathologists, independently and in a blind fashion. 414 
 The intensity of E-Cadherin expression was evaluated and recorded using the Image J 415 
software and by analyzing ROI with similar cell numbers (3 ×630 microscopic fields per 416 
tumor, 3 tumors per group each from different mice). 417 
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The quantification of C3 fragment deposition, pWWOX, C1q and Her2/neu  protein  was 418 
performed  by image analysis with Adobe Photoshop. Positive red fluorescent pixels were 419 
selected using the magic wand tool and quantified in the histogram window in images from 10 420 
tumors per group (3 ×400 microscopic fields per sample) for C3 and C1q quantification and 7 421 
tumors per group (3 ×400 microscopic fields per sample) for pWWOX and Her2/neu protein 422 
quantification. Results are represented as means ± SEM. 423 
The number and the lumen area of CD31+/CD105+ vessels were evaluated on the digital 424 
images of 3-5 tumors per group (5 x200 microscopic fields per tumor) by 2 pathologists, 425 
independently and in a blind fashion. Vessels area (in pixels) was evaluated with Adobe 426 
Photoshop by selecting vessels with the lasso tool and reporting the number of pixels 427 
indicated in the histogram window. 428 
 429 
Protein preparation and immunoblotting. Total protein extracts were obtained from 430 
neuT, neuT-C1KO and neuT-C3KO mammary tumors. Briefly flash frozen specimens were 431 
dissociated using an IKA-Ultra-Turrax® T8 homogenizer (IKA-Werke, Staufen Germany) in a 432 
buffer containing 10mM Tris, 5 mM EDTA, 50 mM NaCl, 30 mM Sodium pyrophosphate 433 
decahydrate (Na4O7P2-10H2O), 50 mM Sodium Fluoride (NaF), 1 mM Sodium orthovanadate 434 
(Na3VO4), 1% Triton X (Adjust the pH 7.6), 1 mM Phenylmethanesulfonyl fluoride100 (all 435 
from Sigma-Aldrich) and a cocktail of protein inhibitors (Sigma-Aldrich, P8340). Samples 436 
were then centrifuged twice at 12000 rpm at 4°C for 5 minutes. 40 μg of total proteins, as 437 
determined by BCA Protein Assay (Pierce, Thermo Fisher), were separated by SDS-PAGE and 438 
electroblotted onto polyvinylidene fluoride membranes (BioRad). Membranes were blocked 439 
in 5% BSA (Sigma Aldrich) Tris-buffered saline (TBS)-Tween buffer (137 mM NaCl, 20 mM 440 
Tris/HCl, pH 7.6, 0.05% Tween-20) for 1 h at RT and then incubated with appropriate 441 
primary (anti e-Cadherin, Cell Signaling, 3195; anti β-actin, Santa Cruz Biotechnology, sc-442 
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69879) and appropriate secondary antibodies (goat anti-rabbit, Sigma_Aldrich, A0545 and 443 
goat anti mouse Sigma_Aldrich, A4416, respectively) in 3% BSA TBS-Tween buffer overnight 444 
at 4° C and for 1 h at room temperature, respectively, and visualized using enhanced 445 
chemiluminescence (ECL Plus, Thermo Scientific Pierce). Protein modulations were 446 
normalized on the actin loading control and expressed as Adjusted Volume Intensity/mm2 447 
(background subtraction) using Quantity ONE software (Biorad, Milano, Italy). 448 
 449 
Cytometric identification of tumor infiltrating leukocytes. For the infiltrating-cell 450 
phenotypic analyses, fresh primary tumor specimens of 6-8 mm mean diameter from 5 neuT, 451 
7 neuT-C1KO and 6 neuT-C3KO mice were finely minced with scissors and then digested by 452 
incubation with 1 mg/ml collagenase IV (Sigma Aldrich) in RPMI-1640 (Life Technologies) at 453 
37° C for 1 h in an orbital shaker. After washing in PBS supplemented with 2% fetal bovine 454 
serum (GIBCO), the cell suspension was incubated in an erylise buffer (155mM NH4Cl, 455 
15.8mM Na2CO3, 1mM EDTA, pH 7.3) for 10 minutes at RT. After washing in RPMI-1640 456 
supplemented with 10% FBS, the cell suspension was passed through a 70-µm pore cell 457 
strainer, centrifuged at 1400 rpm for 10 min and re-suspended in an erylise buffer. Tumor 458 
infiltrating leukocytes were collected, washed, re-suspended in PBS, treated with Fc receptor 459 
blocker (anti CD16/CD32; 01245B; BD Bioscences), and stained with the following antibodies: 460 
anti-mouse CD45 VioGreen (Miltenyi Biotec, 130097), anti-mouse CD3 FITC (Miltenyi Biotec, 461 
130-092962), anti-mouse CD4 APC-Vio770 (Miltenyi Biotec, 130-102-179), anti-mouse CD8 462 
VioBlue (Miltenyi Biotec, 130-094-360), anti-mouse γδ PE/Cy7 (BioLegend, 118124), anti-463 
mouse CD49b PE (Miltenyi Biotec, 130-091-816), anti-mouse F4/80 APC (Miltenyi Biotec, 464 
130-102-379), anti-mouse CD11b FITC (Miltenyi Biotec, 130-081-201), and anti-mouse GR-1 465 
PE (Miltenyi Biotec, 130-102-426). To detect FoxP3+ T regulatory cells, samples were 466 
permeabilized with the FoxP3 anti-mouse staining kit (eBioscience) and stained with the anti-467 
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mouse/rat-Foxp3-FITC antibody (eBioscience, FJK-16s;). Samples were acquired and 468 
analyzed on a CyAn ADP flow cytometer using Summit 4.3 software (Beckman Coulter, 469 
Milano, Italy).  470 
  471 
Captions to figures 472 
 473 
Figure 1. C1q deficiency is responsible for accelerated tumor growth in neuT mice. 474 
Tumor incidence (A) and multiplicity (B) of mammary carcinomas in neuT (n = 30, gray line) 475 
and neuT-C1KO (n = 18, black line) mice. Earlier incidence (*** p<0.0001, Log-rank Mantel-476 
Cox Test) and higher tumor multiplicity (starting from the 17th week of age, p values ranging 477 
from p=0.04 to p<0.0001, Student’s t-test) were found in neuT-C1KO as compared to neuT 478 
mice. C: Time required for a 2 mm mean diameter tumor to reach an 8 mm threshold. Tumors 479 
that arose in neuT-C1KO (black bar) mice grew significantly faster than those growing in neuT 480 
(grey bar) mice (** p=0.001, two-tailed Student’s t-test). (D-I) Representative whole mount 481 
images of the fourth (inguinal) mammary glands of 11- (D, G), 15- (E-H), 17- (F, I) week-old 482 
neuT (D-F) and neuT-C1KO (G-I) mice. The central oval black shadows are the intra-483 
mammary lymph nodes. Magnification x6.3. (J, K) Histological and immunohistochemical 484 
staining for the PCNA of mammary tumor lesions in neuT (J) and neuT-C1KO (K) mice. 485 
Magnification x400. PCNA+ tumor cell quantification (L) in neuT (grey bar) and in neuT-C1KO 486 
(black bar) mice (** p=0.001, two-tailed Student’s t-test). (M, N) Histological and 487 
immunohistochemical staining for the active caspase-3 in mammary tumor lesions of neuT 488 
(M) and neuT-C1KO (N) mice. Black arrows indicate apoptotic tumor cells. Magnification 489 
x400. Active caspase-3+ tumor cell quantification (O) in neuT (grey bar) and in neuT-C1KO 490 
(black bar) mice (** p=0.002, two-tailed Student’s t-test).  491 
 492 
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Figure 2. C1q deficiency is associated with anticipated metastatic spread and epithelial-493 
to-mesenchymal transition in neuT tumors. Histological and immunohistochemical 494 
staining for Her2/neu of lungs from 17-week-old neuT (A) and neuT-C1KO (B) mice reveal 495 
earlier metastatic infiltration in neuT-C1KO mice. Magnification x400. (C): Percentage of neuT 496 
(n = 19, grey bar) and neuT-C1KO (n = 14, black bar) mice (*p=0.05 Chi-square test) bearing 497 
lung metastatic lesions at 17 weeks of age. (D-I) Decreased expression of E-Cadherin in neuT-498 
C1KO and neuT-C3KO vs. neuT tumors. (D) E-Cadherin (upper panel) and actin (lower panel) 499 
protein levels as measured using the immunoblotting of whole cell lysates from 6-8 mm mean 500 
diameter carcinomas. A representative blot from three independent experiments is shown. 501 
(E) Quantification of E-Cadherin protein expression in neuT (grey bar), in neuT-C1KO (black 502 
bar) and neuT-C3KO (white bar) tumors (*p<0.05, two-tailed Student’s t-test). (F-H) 503 
Representative microscopy images of tumor sections from neuT (F), neuT-C1KO (G) and 504 
neuT-C3KO (H) mice (n = 3 per group) labeled with anti-E-Cadherin antibody (red) and DAPI 505 
(blue, labeling nuclei). Magnification x400. (I) E-Cadherin protein was quantified in neuT 506 
(grey bar), neuT-C1KO (black bar) (***p<0.0001, two-tailed Student’s t-test) and neuT-C3KO 507 
(white bar) tumors (*p=0.04, two-tailed Student’s t-test). Results are represented as means ± 508 
SEM. 509 
 510 
Figure 3. The dispensable role of the classical complement activation pathway in neuT 511 
tumor immunosurveillance. C3 fragment deposition at the tumor site is not altered in the 512 
absence of C1q or antibodies. (A-C) Confocal microscopy images representative of frozen 513 
tumor sections from mammary glands of 17-week-old neuT (A), neuT-C1KO (B) and neuT-514 
BKO (C) mice labeled with anti-C3b/iC3b/C3c antibody (red) and TO-PRO®-3 iodide (blue). 515 
Magnification x400. C3 fragment deposition was quantified (D) in neuT (grey bar), neuT-516 
C1KO (black bar) and neuT-BKO (white bar) mice (n = 10 each group). No differences in C3 517 
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fragments deposition were found (p=ns, two-tailed Student’s t-test). Results are represented 518 
as means ± SEM from 3 x400 microscopic fields per sample. 519 
 520 
Figure 4. Decrease of pWWOX and increase of Her2/neu expression in neuT-C1KO 521 
tumors. Confocal microscopy images of frozen tumor sections from neuT (A, E, I), neuT-C1KO 522 
(B, F, J) and neuT-C3KO (C, G, K) mice (n = 7 per group) labeled with anti-pWWOX (red, A-C), 523 
anti-C1q (red, E-G) and anti-Her2/neu (red, I-K) antibodies. Nuclei were stained with TO-524 
PRO®-3 iodide (blue). Magnification x100. pWWOX (D), C1q (H) and Her2/neu (L) protein 525 
quantification was performed in neuT (grey bar), neuT-C1KO (black bar) and neuT-C3KO 526 
(white bar) mice (*p=0.02 for pWWOX;  *p=0.04 and **p=0.009 for C1q; *p≤0.04 for 527 
Her2/neu;  two-tailed Student’s t-test). Results are represented as means ± SEM from 3 x400 528 
microscopic fields per sample. 529 
 530 
Figure 5. C1q deficiency affects intratumoral vessel density but does not modify tumor 531 
infiltrating leukocyte recruitment. (A–C) Representative images of immunohistochemical 532 
staining for endothelial cell markers (CD31 and CD105, red) to visualize blood vessels in 533 
mouse tumors of equal volume developed in neuT (A) neuT-C1KO (B) and neuT-C3KO (C) 534 
mice. Magnification x200. Quantification of the number (D) of vessels in neuT (gray bar; n = 535 
3), neuT-C1KO (black bar; n = 5) and neuT-C3KO (white bar; n = 5) carcinoma (*p=0.04; two-536 
tailed Student’s t-test). Results are represented as means ± SEM from 5 x200 microscopic 537 
fields per sample. (E–H) Representative confocal microscopy images of tumors from neuT (E) 538 
neuT-C1KO (F) and neuT-C3KO (G) mice stained with anti-CD31 antibodies (green). 539 
Magnification x400. Quantification of the vessel area (H) in neuT (gray bar; n = 3), neuT-C1KO 540 
(black bar; n = 5) and neuT-C3KO (white bar; n = 5) carcinoma. (***p<0.0001; two-tailed 541 
Student’s t-test)Results are represented as means ± SEM from 5 ×200 microscopic fields. (I-542 
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M) Flow cytometry analysis of infiltrating leukocytes in 6-8 mm mean diameter tumors from 543 
neuT (n = 5; gray bars), neuT-C1KO (n = 7; black bars) and neuT-C3KO (n = 6; white bars) 544 
mice. (I) CD3+ leukocytes were gated and CD3+ CD4+ CD25+ FoxP3+ were identified as Tregs 545 
(**p=0.005; two-tailed Student’s t-test). (L) CD45+ leukocytes were gated and CD3+ CD4+ cells 546 
were identified as CD4 T, CD3+ CD8+ as CD8 T, CD3+ γδ+ as γδ T and CD3- CD49b+ as NK 547 
(**p=0.005;  two-tailed Student’s t-test). (M) CD45+ CD11b+ leukocytes were gated and 548 
F4/80+ cells were identified as macrophages (MΦ) while GR-1+ cells were identified as 549 
myeloid derived suppressor cells (MDSC). Bars represent the percentage of positive cells ± 550 
SEM.  551 
 552 
Figure 6. NeuT-C1KO tumors are less aggressive than those of neuT-C3KO mice. Tumor 553 
incidence of mammary carcinomas (A) and overall mice survival (B) in neuT (n = 20, 554 
continuous gray line), neuT-C1KO (n = 14, continuous black line) and neuT-C3KO (n = 15, 555 
dotted black line) mice. Neu-T-C3KO mice displayed earlier tumor incidence (*p=0.05, Log-556 
rank Mantel-Cox Test) and lower overall survival (*p=0.02, Log-rank Mantel-Cox Test) than 557 
neuT-C1KO mice. 558 
 559 
Figure 7. Proposed mechanism of C1q influence on neuT tumor progression. C1q 560 
component of C1 complex (C1q, C1s and C1r) appears to act directly both on tumor 561 
vasculature (on the right) and on tumor cells (on the left). Deposition of C1q on vascular 562 
endothelium inhibits tumor angiogenesis through a still undefined mechanism. C1q binding 563 
with its receptor(s) (C1qR) on tumor cells leads to the phosphorylation of tyrosine 33 (Y33) 564 
on WWOX. Activated WWOX in turn inhibits the EMT processes, through the expression of E-565 
Cadherin, and induces Caspase-3-mediated apoptosis, probably by engaging p53. We 566 
hypothesize activated WWOX may be also involved in neuT post-translational negative 567 
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regulation further contributing to tumor inhibition. Green lines: anti-tumor activities; red 568 
lines: pro-tumor activities. 569 
 570 
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